CD8A and neoplasm: When comparing PRGN-2009–treated mice (Best Responders only) with PBS controls (Table 1, bottom), the previously stated trends continued to expand, with approximately 50 times more CD8+ T cells per mg of tumor in Best Responder mice compared with controls, and even higher ratios for multifunctional and activated CD8+ T cells (Table 1, bottom).